Braftovi® (encorafenib)
for Colorectal Cancer

Braftovi (encorafenib) is a targeted kinase inhibitor used in combination with other therapies to treat cancers with a specific BRAF mutation. It is prescribed with Mektovi for metastatic melanoma and NSCLC, and with Erbitux (with or without mFOLFOX6) for metastatic colorectal cancer. Braftovi blocks the overactive BRAF protein, slowing cancer growth. It is not chemotherapy but a targeted treatment designed to disrupt cancer cell signaling pathways.

Heart
Medication Guide Icon Medication Guide
Patient Website Icon Patient Website
Efficacy Data Icon Efficacy Data
New Articles Icon New Articles
Savings and Support Icon Savings and Support
Company MD Payments Icon Company MD Payments
Clinical Trials Icon Clinical Trials
Adverse Event Report Icon Adverse Event Report
Other top medicines used to treat Colorectal Cancer - CRC